Oxford Medical Diagnostics Continue With Next Phase Of Development Of Their Breath Ketone Analysis Platform.

18 March 2015

New non invasive system aims to reduce the incidence of Diabetic KetoAcidosis.

Oxford Medical Diagnostics (OMD), a leading developer of advanced proprietary methods of analysing volatile organic compounds (VOCs) in breath, is working with Renfrew Group International (RGi) for the engineering and industrial design of a portable breath analysis device.

The collaboration will combine OMD’s scientific research expertise with RGi’s design capabilities to further develop an accurate, low-cost, portable and non-invasive breath analysis platform to identify and monitor certain metabolic and infectious diseases by detecting and measuring VOCs in breath.

OMD’s platform is based on the Company’s main proprietary technology, Cavity Enhanced Absorption Spectroscopy (CEAS), which was developed at the University of Oxford. The current prototype device is capable of measuring acetone in breath samples at sub-parts-per-million levels, which is in excess of the sensitivity required to detect acetone levels of patients with Type 1 diabetes.

OMD has been awarded further SBRI funding and two TSB grants to support the development of multiple units for the next phase of clinical trials in collaboration with an expert team at AddenbrookesHospital in Cambridge under the direction of Dr Mark Evans.

The device is designed for use in Type 1 diabetes, as an aid to diabetes management and to help prevent the onset of Diabetic KetoAcidosis (DKA). In recent months the prototype system was successfully used in its first clinical evaluation, successfully measuring breath acetone from over 100 samples.

The early model (Pictured) will support obesity prevention and is currently being tested and evaluated in clinics. A smaller consumer orientated device is also being developed.


Med-Tech Innovation Expo